Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors

J Clin Microbiol. 2005 Jan;43(1):484-7. doi: 10.1128/JCM.43.1.484-487.2005.

Abstract

We described the baseline polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene from 94 treatment-naive patients and the longitudinal follow-up of 17 protease inhibitor-treated patients. Compared to the HIV-2 consensus sequences, baseline polymorphism involved 47 positions. Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Drug Resistance, Viral / genetics
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease / genetics*
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use
  • HIV-2 / drug effects
  • HIV-2 / enzymology
  • HIV-2 / genetics
  • Humans
  • Male
  • Mutation*
  • Polymorphism, Genetic*

Substances

  • HIV Protease Inhibitors
  • HIV Protease